Clinical Trial Update: Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating PEG-rhG-CSF to prevent neutropenia during concurrent chemoradiotherapy for cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Cervical Cancer | Phase 2 | Status: COMPLETED